Catalog No.
DHC27702
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
3.95mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ChAglyCD, TRX4, CAS: 881191-44-2
Clone ID
Otelixizumab
Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus, PMID: 21913874
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus, PMID: 27145230
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside, PMID: 27161438
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes, PMID: 33145642
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients, PMID: 30566758
Targeting T cells in inflammatory bowel disease, PMID: 32585338
Otelixizumab in the treatment of type 1 diabetes mellitus, PMID: 22053883
Molecule of the month. Otelixizumab, PMID: 20520855
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes, PMID: 25011949
Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients, PMID: 27023009
Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes, PMID: 20147616
Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static culture, PMID: 26341624
Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus, PMID: 19934031
Urinary C-peptide analysis in an intervention study: experience from the DEFEND-2 otelixizumab trial, PMID: 26871270
Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes, PMID: 25583753
Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study, PMID: 24236828
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial, PMID: 21719095
A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease, PMID: 24704524
Prospects for therapeutic tolerance in humans, PMID: 24378931
Anti-CD3 clinical trials in type 1 diabetes mellitus, PMID: 23726024
Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases, PMID: 23254986
Immunotherapies in diabetes mellitus type 1, PMID: 22703858
Emerging treatments for the prevention of type 1 diabetes, PMID: 20384544
Anti-CD3 mAbs for treatment of type 1 diabetes, PMID: 19319985
Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice, PMID: 29030662
Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance, PMID: 31523950
CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic, PMID: 23804274
Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes, PMID: 21864261
Immunomodulators: Cell savers, PMID: 22616095
Type 1 diabetes pathogenesis - Prevention???, PMID: 25941654
Antibody-based therapeutics to watch in 2011, PMID: 21051951
Biologic therapies in type 1 diabetes: how far are they from us?, PMID: 24229664
Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance, PMID: 21289272
Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients, PMID: 22069286
Studies in human intestinal tissues: is it time to reemphasize research in human immunology?, PMID: 24877864
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes, PMID: 29925930
Anti-CD3 antibodies for type 1 diabetes: beyond expectations, PMID: 21719098
Prevention and reversal of type 1 diabetes--past challenges and future opportunities, PMID: 25998292
Development of a quantitative assay to measure EBV viral load in patients with autoimmune type 1 diabetes and healthy subjects, PMID: 19931313
Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration, PMID: 26073995
Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry, PMID: 22366323
[Antibodies instead of insulin?], PMID: 20196056
For research use only. Not for human or drug use.
